In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates

Dae Hun Kim, Byung Woo Jhun, Seong Mi Moon, Su Young Kim, Kyeongman Jeon, O. Jung Kwon, Hee Jae Huh, Nam Yong Lee, Sung Jae Shin, Charles L. Daley, Won Jung Koh

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii. However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii. Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.

Original languageEnglish
Article numbere00665-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number8
DOIs
Publication statusPublished - 2019

Bibliographical note

Funding Information:
This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.).

Funding Information:
This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.). C.L.D. has received grants from Insmed, Inc., and served on advisory boards for Otsuka, Insmed, Johnson and Johnson, Spero, and Horizon, not associated with the submitted work. W.-J.K. has received a consultation fee from Insmed, Inc., for the Insmed advisory board meeting, not associated with the submitted work. Otherwise, we have no conflicts of interest to declare.

Publisher Copyright:
Copyright © 2019 American Society for Microbiology. All Rights Reserved.

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates'. Together they form a unique fingerprint.

Cite this